Dr Martin Bollmark

Research activities in the group of Tedebark and Bollmark are focused on orthogonal conjugation techniques to obtain constructs containing combination of oligonucleotide derivatives and at least one other entity from the groups of peptides, proteins (mAb), carbohydrates, lipids or small molecules to allow targeted delivery and tailored release conditions at the site of action. This involves organic chemistry transformation and introduction of handles for selective conjugation as well as preparation of larger amounts of building blocks. The laboratory (being the former Process Development and Pharmaceutical Department of AstraZeneca) has full access to equipment to facilitate process development of larger scale synthesis of building blocks and automated synthesis instruments for subsequent introduction into oligomers.